Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.56 |
| ▸ | IDO1 | P14902 | 2/20 | 0.43 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.37 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.37 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.37 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.37 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.37 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.37 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.37 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.37 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.37 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.37 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30769022 | 1.00 | TAAR1 (0.56) | TAAR1IDO1GPR52POLBTSHR | |
| SCHEMBL3028718 | 0.93 | TAAR1 (0.54) | TAAR1IDO1GPR52TSHRALDH1A1 | |
| SCHEMBL9026542 | 0.91 | TAAR1 (0.52) | TAAR1IDO1GPR52TSHRALDH1A1 | |
| SCHEMBL286557 | 0.86 | TAAR1 (0.60) | TAAR1IDO1GPR52TSHRALDH1A1 | |
| SCHEMBL29590438 | 0.86 | TAAR1 (0.60) | TAAR1IDO1GPR52TSHRALDH1A1 | |
| Phosphine SCHEMBL8416873 | 0.84 | TAAR1 (0.58) | TAAR1IDO1GPR52TSHRALDH1A1 | |
| SCHEMBL29681348 | 0.83 | TDP1 (0.43) | TAAR1POLB | |
| SCHEMBL1607140 | 0.83 | TDP1 (0.43) | TAAR1POLB | |
| SCHEMBL29681353 | 0.83 | TDP1 (0.43) | TAAR1POLB | |
| SCHEMBL29351396 | 0.80 | TAAR1 (0.71) | TAAR1IDO1GPR52TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 188 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013102935-A2 | Cu-MEDIATED ANNULATION FOR THE EFFECTIVE SYNTHESIS OF 3-SUBSTITUTED PHTHALIDES | COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) | 2013-07-11 | — | — | WO | claimed |
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | RELAY THERAPEUTICS, INC. | 2025-12-25 | — | — | US | disclosed |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4543871-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND USE THEREOF | Relay Therapeutics, Inc. (US) | 2025-04-30 | — | — | EP | disclosed |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-12-17 | — | — | US | disclosed |
| CN-118955244-A | Method for preparing primary alcohol by homogeneously catalyzing and reducing carboxylic acid derivative by using N-heterocyclic carbene copper complex | 延安大学 | 2024-11-15 | — | — | CN | disclosed |
| WO-2024095734-A1 | FLUORINE-CONTAINING HETEROCYCLIC COMPOUND PRODUCTION METHOD, AND FLUORINE-CONTAINING COMPOUND PRODUCTION METHOD | ＡＧＣ株式会社 | 2024-05-10 | — | — | WO | disclosed |
| CN-111925360-B | 1-heterocyclylisochromanyl compounds and analogs for the treatment of CNS disorders | 赛诺维信制药公司 | 2024-03-22 | — | — | CN | disclosed |
| CN-112279808-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-03-08 | — | — | CN | disclosed |
| CN-112250627-B | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2024-02-02 | — | — | CN | disclosed |
| EP-0497629-A1 | Heterocyclic amido prostaglandin analogs | E.R. SQUIBB & SONS, INC. (US) | 1992-08-05 | — | — | EP | disclosed |
| US-5135939-A | HETEROCYCLIC KETONE PROSTAGLANDIN ANALOGS | E. R. SQUIBB & SONS, INC. (US) | 1992-08-04 | — | — | US | disclosed |
| US-5126370-A | Anti-thrombotic heterocyclic amido prostaglandin analogs | E. R. SQUIBB & SONS, INC. (US) | 1992-06-30 | — | — | US | disclosed |
| US-5100889-A | Thromboxane A2 receptor antagonists, thromboxane synthetase inhibitor | E. R. SQUIBB & SONS, INC. (US) | 1992-03-31 | — | — | US | disclosed |
| EP-0476994-A1 | 7-Oxabicycloheptyl substituted heterocyclic thioamide prostaglandin analogs useful in the treatment of thrombotic and vasospastic disease | E.R. SQUIBB & SONS, INC. (US) | 1992-03-25 | — | — | EP | disclosed |
| EP-0447188-A2 | 7-Oxabicycloheptane imidazole prostaglandin analogs useful in the treatment of thrombotic and vasospastic diseases | E.R. SQUIBB & SONS, INC. (US) | 1991-09-18 | — | — | EP | disclosed |
| US-4977174-A | Anticoagulants, antischemic agents | E. R. SQUIBB & SONS, INC. (US) | 1990-12-11 | — | — | US | disclosed |
| EP-0391652-A1 | Interphenylène 7-oxabicycloheptyl substituted heterocyclic amide prostaglandin analogs useful in the treatment of thrombotic and vasopastic disease | E.R. SQUIBB & SONS, INC. (US) | 1990-10-10 | — | — | EP | disclosed |
| US-4001233-A | CNS STIMULANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1977-01-04 | — | — | US | disclosed |
| US-3957787-A | CENTRAL NERVOUS SYSTEM STIMULANTS, MUSCLE RELAXANTS | E. R. SQUIBB & SONS, INC. (US) | 1976-05-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250388565-A1 | ESTROGEN RECEPTOR ALPHA DEGRADERS AND METHODS OF USE THEREOF | ESRRA, ESRRB, ESR2 | TAAR1 780/4885IDO1 3040/4885GPR52 360/4885 |
| US-20250205232-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, SCNN1B, SLC26A4 | TAAR1 2181/4885IDO1 4683/4885GPR52 358/4885 |
| US-12168009-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | CFTR, SCNN1B, SLC26A4 | TAAR1 2181/4885IDO1 4683/4885GPR52 358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.